Skip to main content
. 2014 Nov 4;9(11):e111610. doi: 10.1371/journal.pone.0111610

Table 1. Patient characteristics and transplant variables.

All Patients (n = 190) Survivors (n = 117) Non survivors (n = 73) p value
Age (years) 51±13 50±13 52±13 0.300
Male gender 115 (60.5) 61 (52.1) 54 (73.9) 0.002
Body mass index (kg/m2) 24±5 25±5 23±4 0.003
Comorbidities
Hypertension 152 (80.0) 99 (84.6) 53 (72.6) 0.040
Diabetes mellitus 61 (32.1) 39 (33.3) 22 (30.1) 0.600
CAD 35 (18.4) 24 (20.5) 11 (15.0) 0.300
Stroke 8 (4.2) 6 (5.1) 2 (2.7) 0.700
CHF 5 (2.6) 3 (2.5) 2 (2.7) 1.000
Hepatitis C 13 (6.8) 7 (5.9) 6 (8.2) 0.500
Hepatitis B 6 (3.1) 3 (2.5) 3 (4.1) 0.600
COPD 6 (3.1) 1 (0.8) 5 (6.8) 0.030
ESRD etiology 0.220
Undetermined 67 (35.2) 41 (35.0) 26 (35.6)
Glomerulonephritis 50 (26.3) 33 (28.2) 17 (23.2)
Diabetes mellitus 36 (18.9) 18 (15.3) 18 (24.6)
Hypertension 28 (14.7) 21 (17.9) 7 (9.5)
Urologic disease 9 (4.7) 4 (3.4) 5 (6.8)
Dialysis modality before transplant 0.480
Preemptive 8 (4.2) 7 (5.9) 1 (1.3)
Hemodialysis 153 (80.5) 91 (77.7) 62 (84.9)
Peritoneal 21 (11.0) 14 (11.9) 7 (9.5)
Hemodialysis/peritoneal 8 (4.2) 5 (4.2) 3 (4.1)
Time of dialysis (months) 34 (18–60) 32 (18–60) 36 (24–68) 0.170
Donor type 0.190
Deceased 122 (64.2) 71 (60.6) 51 (69.8)
Living 68 (35.8) 46 (39.4) 22 (30.2)
Donor gender a 0.330
Female 71 (42.0) 43 (40.6) 28 (44.5)
Male 98 (58.0) 63 (59.4) 35 (55.5)
Deceased donor b
Cause of death c 0.930
 Traumatic brain injury 33 (28.0) 21 (30.0) 12 (25.0)
 Subarachnoid hemorrhage 20 (16.9) 12 (17.1) 8 (16.6)
 Stroke 56 (47.5) 32 (45.7) 24 (50.0)
 Others 9 (7.6) 5 (7.2) 4 (8.4)
Panel reactive antibodies d 0.660
 0–50% 93 (84.5) 55 (83.3) 38 (86.3)
 >51% 17 (15.5) 11 (16.7) 6 (13.6)
Final creatinine e 0.210
<1.5 mg/dL 31 (32.6) 21 (35.5) 10 (27.7)
≥1.5 mg/dL 64 (67.4) 38 (64.5) 26 (72.3)
Cold ischemia time (hours) f 23 (20–27) 23 (20–28) 22 (20–27) 0.630
Expanded criteria donor 31 (26.3) 13 (18.6) 18 (37.5) 0.020
Delayed graft function 82 (43.3) 44 (37.6) 38 (52.7) 0.040
Thymoglobulin use g 54 (28.5) 34 (29.0) 20 (27.7) 0.870
CMV disease treated 68 (35.9) 41 (35.0) 27 (37.5) 0.750
Current immunosuppression h 0.460
TAC+PRED+AZA 31 (16.3) 16 (13.6) 15 (20.5)
TAC+PRED+MF 70 (36.8) 48 (41.0) 22 (30.1)
CSA+PRED+AZA 17 (8.9) 12 (10.2) 5 (6.8)
CSA+PRED+MF 7 (3.6) 4 (3.4) 3 (4.1)
TAC/CSA+PRED+EVR/SRL 4 (2.1) 3 (2.5) 1 (1.7)
SRL/EVR+PRED+MF 9 (4.7) 4 (3.4) 5 (6.8)
Others 51 (26.8) 30 (25.6) 21 (28.7)
Time between transplant and sepsis (years) 2.1 (0.6–7.2) 2.3 (0.6–7.8) 1.6 (0.6–7.0) 0.600
Acute rejection 55 (28.9) 34 (29.0) 21 (28.7) 0.960
Time rejection-sepsis (days) i 312 (130–776) 331(115–817) 282 (152–849) 0.900

CAD coronary artery disease, CHF: congestive heart failure, COPD: chronic obstructive pulmonary disease, ESRD: end-stage renal disease, CMV: cytomegalovirus, TAC: tacrolimus, PRED: prednisone, AZA: azathioprine, MF: mycophenolate, CSA: cyclosporine, EVR: everolimus, SRL sirolimus.

a) 21 missing data,

b) 122 deceased donors,

c) 4 missing data,

d) 12 missing data,

e) final creatinine refers to the donors' last serum creatinine level, 27 missing data,

f) 3 missing data,

g) patients who used thymoglobulin for treating rejection and/or induction in transplantation,

h) 1 missing data and i) time between the occurrence of rejection and sepsis (total of patients with rejection, 55 patients, 3 patients among the survivors and 6 among the non-survivors were excluded for missing data). The results are expressed as number (%) or median (IQR, 25%–75%) or mean ± standard deviation. Chi-squared test, Mann-Whitney U-test, and Student's t-test (univariate analysis).